SLU-PP-332

None

Rank#999
OtherNot ApprovedAnimalResearchSubQOral

Popular for:Exercise mimetic, ERR-alpha agonist, endurance research

9

Total Studies

4

Human Studies

Animal

Evidence Level

Not Approved

FDA Status

Overview

SLU-PP-332 is a synthetic small molecule pan-agonist of the estrogen-related receptor (ERR) family — specifically ERRα, ERRβ, and ERRγ. Developed at Washington University in St. Louis (hence 'SLU'), it is classified as an 'exercise mimetic' — a compound that activates the same genetic programs triggered by aerobic exercise without requiring physical exertion.

> SLU-PP-332 is a pre-clinical research compound. It has NOT been tested in humans. All data is from mouse/cell studies. No human safety or dosing data exists.

Mechanism of Action

SLU-PP-332 binds to ERR nuclear receptors (EC50: ERRα = 98 nM, ERRβ = 230 nM, ERRγ = 430 nM in cell-based assays). These receptors regulate mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation — the same pathways upregulated by endurance exercise. ERRα activation is critical for the exercise-mimicking effects. The compound induces a shift from Type II (fast-twitch glycolytic) to Type I (slow-twitch oxidative) muscle fibers.

Key Research Benefits

Enhanced exercise endurance: Mice treated with SLU-PP-332 ran ~70% longer and ~45% farther on treadmill tests (Xia et al., 2023, ACS Chemical Biology).
Muscle fiber type conversion: Increased proportion of slow-twitch oxidative (Type I) fibers in skeletal muscle, mimicking endurance training adaptations.
Metabolic syndrome improvement: In obese mice, SLU-PP-332 alleviated metabolic syndrome markers — reduced body weight, improved fatty acid oxidation, and enhanced mitochondrial function (Wang et al., 2024, J Med Chem).
Anti-aging potential: ERR activation counteracts mitochondrial dysfunction associated with aging. A 2025 pilot study (Frontiers in Physiology) explored ERR agonists for age-related muscle atrophy.
Cardioprotective: ERR agonism has shown benefits in heart failure models by improving cardiac mitochondrial function.

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

9

Total Studies

4

Human Studies

- Xia et al. (2023) — 'Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity' (ACS Chemical Biology). First major publication establishing SLU-PP-332 as an exercise mimetic.

- Wang et al. (2024) — 'A Synthetic ERR Agonist Alleviates Metabolic Syndrome' (J Med Chem, PMID: 37739806). Demonstrated that SLU-PP-332 reduces obesity markers and improves metabolic syndrome in diet-induced obese mice.

- Frontiers in Physiology (2025) — Pilot study exploring ERR agonists for counteracting age-related muscle atrophy from physical inactivity.

- **Clinical Trial Status: **No clinical trials registered. Entirely pre-clinical. Human trials may be years away.

Key Studies / PubMed References

Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.

Review

Okda HE, Zhao P, Hayes M, et al. · International journal of biological macromolecules · 2026

PMID: 41850449

Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.

Human Study

Avliyakulov NK, Sobolevsky T, Ahrens E · Drug testing and analysis · 2026

PMID: 41688415

An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.

Animal Study

Billon C, Appourchaux K, Côté I, et al. · The Journal of pharmacology and experimental therapeutics · 2026

PMID: 41421047

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

In Vitro

Möller T, Krug O, Thevis M · Rapid communications in mass spectrometry : RCM · 2026

PMID: 41588687

Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.

Review

Bonanni R, Falvino A, Matticari A, et al. · Frontiers in physiology · 2025

PMID: 40692696

Side Effects & Safety

> No human safety data exists. All side effect information is from animal models. Using this compound carries unknown risks.

Animal studies: No significant adverse effects were reported in published mouse studies at the doses tested. However, these were short-duration studies.
Theoretical concerns: ERR receptors are expressed in multiple tissues (heart, liver, kidney, brain). Non-selective pan-ERR activation could have unpredictable effects on these organs.
Estrogen receptor concern: Despite the name, ERRs are 'estrogen-related' but do not bind estrogen. No estrogenic activity has been observed.
Long-term safety: Completely unknown. Chronic ERR activation effects on muscle remodeling, cardiac tissue, and metabolism have not been studied.

Known Interactions

No curated interaction entry is live for SLU-PP-332 yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. SLU-PP-332 is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.